Martin Dreyling

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Michael R. Bishop, Michael Dickinson, Duncan Purtill et al. · New England Journal of Medicine · 2021 · 520 citations · Full text

Medicine, Hematology, Oncology +9

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Journal of Clinical Oncology · 2017 · 398 citations

Medicine, Oncology, Pharmacology +13

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Philippe Moreau, Jesús F. San Miguel, Heinz Ludwig et al. · Annals of Oncology · 2013 · 236 citations · Full text

Medicine, Hematology, Oncology +14

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Martin Dreyling, Jeanette K. Doorduijn, Eva Giné et al. · The Lancet · 2024 · 136 citations · Full text

Medicine, Hematology, Oncology +10

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Franck Morschhauser, Saurabh Dahiya, M. Lia Palomba et al. · Nature Medicine · 2024 · 130 citations · Full text

Medicine, Immunology, Oncology +16